Hong Kong, Shanghai & Florham Park, New Jersey – August 28, 2026
HUTCHMED announced that China’s National Medical Products Administration (NMPA) has granted conditional approval for ATLED® (fanregratinib, HMPL-453) for adults with advanced, metastatic or unresectable intrahepatic cholangiocarcinoma (ICC) harboring FGFR2 fusions or rearrangements following prior systemic therapy. The approval establishes ATLED as a targeted treatment option for a genetically defined population of previously treated ICC patients in China. The regulatory decision was supported by data from the Phase II registration cohort of HUTCHMED’s pivotal Phase II/IIIb study in China. For cGxP.wire, the key development is the NMPA approval of fanregratinib and its progression into the commercial treatment setting, strengthening HUTCHMED’s oncology portfolio and expanding targeted treatment options for FGFR2-altered ICC.
HUTCHMED Secures NMPA Approval for ATLED
The NMPA conditional approval allows ATLED® to be used in adult patients with advanced, metastatic or unresectable ICC with confirmed FGFR2 fusion or rearrangement who have previously received systemic therapy. The regulatory decision follows clinical evaluation of fanregratinib in a registration cohort of the ongoing Phase II/IIIb clinical trial (NCT04353375). HUTCHMED reported that the pivotal study met its primary endpoint, with an Independent Review Committee-assessed objective response rate of 42.5% in pretreated advanced ICC patients with FGFR2 fusions or rearrangements. The approval is particularly relevant to the molecularly selected ICC population because FGFR2 alterations occur in an estimated 10% to 15% of ICC patients globally. HUTCHMED plans to leverage its established commercial infrastructure in China to support the introduction of ATLED® following the regulatory decision, while the confirmatory Phase IIIb portion of the clinical program continues.
ATLED Demonstrates Clinical Activity in FGFR2-Altered ICC
Clinical data supporting the approval showed additional measures of activity for fanregratinib, including a median time to response of 1.4 months, indicating relatively rapid tumor responses among responding patients. The study reported a median duration of response of 6.9 months and a disease control rate of 83.9%. Median progression-free survival was also 6.9 months, while median overall survival reached 16.6 months. The results provide the clinical basis for continued development of ATLED® in patients whose tumors carry FGFR2 fusions or rearrangements. Fanregratinib is an oral, selective inhibitor targeting FGFR1, FGFR2 and FGFR3, signaling proteins implicated in tumor growth and other cancer-related processes. By targeting aberrant FGFR signaling, HUTCHMED is developing ATLED® as a precision medicine approach for a molecularly defined subgroup of patients with advanced ICC. The current approval is conditional, with additional evidence expected from the ongoing confirmatory development program.
Advertisement
HUTCHMED Continues Confirmatory Phase IIIb Program
The Phase IIIb portion of the study is intended to serve as the confirmatory clinical trial for ATLED® and further evaluate its clinical benefit and safety in the approved patient population. HUTCHMED initiated enrollment into the confirmatory cohort in January 2026, making continued clinical development an important next step following the NMPA decision. The company’s approval of ATLED® adds another targeted therapy to its growing commercial oncology portfolio while maintaining focus on biomarker-driven treatment strategies. Intrahepatic cholangiocarcinoma remains an aggressive form of biliary cancer with historically poor outcomes, creating a significant need for additional treatment approaches after systemic therapy. The FGFR2-focused indication gives ATLED® a defined precision-oncology positioning in China. The immediate regulatory milestone is therefore the transition of fanregratinib from clinical development into commercial availability, while the confirmatory Phase IIIb study will provide additional evidence to support the therapy’s longer-term role in FGFR2-altered intrahepatic cholangiocarcinoma.
Source:HUTCHMED,press relese
